Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension

被引：8
|
作者：
Koo, Rachel [1 ]
Lo, Jennifer [2 ]
Bock, Matthew J. [2 ]
机构：
[1] Loma Linda Univ Childrens Hlth, Dept Pediat, Loma Linda, CA USA
[2] Loma Linda Univ Childrens Hlth, Div Pediat Cardiol, Loma Linda, CA USA
来源：
CARDIOLOGY IN THE YOUNG | 2019年 / 29卷 / 06期
关键词：
Selexipag; infant; prostacyclin; pulmonary hypertension; paediatric;
D O I：
10.1017/S1047951119001082
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.
引用
下载
收藏
页码：849 / 851
页数：3
相关论文
共 50 条
  • [1] Transition From Inhaled Treprostinil to Selexipag in Pulmonary Arterial Hypertension
    El-Kersh, Karim
    Smith, J. Shaun
    AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (05) : E620 - E621
  • [2] TRANSITION FROM SELEXIPAG TO ORAL TREPROSTINIL IN A PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
    Patel, Amol
    Safdar, Zeenat
    CHEST, 2018, 154 (04) : 1023A - 1024A
  • [3] Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
    Oriaku, Ifeoma
    Patel, Amol
    Safdar, Zeenat
    PULMONARY CIRCULATION, 2020, 10 (01)
  • [4] Transition From Oral Treprostinil to Selexipag in a Patient With Pulmonary Arterial Hypertension
    Verlinden, Nathan J.
    Walter, Claire
    Kanwar, Manreet
    Raina, Amresh
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (07) : 764 - 765
  • [5] TRANSITION OF IV TREPROSTINIL TO ORAL SELEXIPAG IN PULMONARY ARTERIAL HYPERTENSION
    Mahoney, Roshan
    Sweidan, Alexander
    Yaghmour, Bassam
    CHEST, 2021, 160 (04) : 2229A - 2229A
  • [6] Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series
    Fanous, Sherif M.
    Janmohamed, Munir
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (23) : 1877 - 1881
  • [7] Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
    Asuka Furukawa
    Yuichi Tamura
    Hiroya Iwahori
    Masato Goto
    Narutaka Ohashi
    Teruo Okabe
    Akio Kawamura
    BMC Pulmonary Medicine, 17
  • [8] Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
    Furukawa, Asuka
    Tamura, Yuichi
    Iwahori, Hiroya
    Goto, Masato
    Ohashi, Narutaka
    Okabe, Teruo
    Kawamura, Akio
    BMC PULMONARY MEDICINE, 2017, 17
  • [9] Uptitration of Pulmonary Arterial Hypertension Therapies: Transition From Oral Selexipag to Parenteral Treprostinil
    Krishnan, M.
    Gomberg-Maitland, M.
    Dias-Douglas, J. M.
    Sherner, J.
    Choi, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S560 - S560
  • [10] Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
    Yanaka, Kenichi
    Guillien, Alicia
    Soumagne, Thibaud
    Benet, Justin
    Piliero, Nicolas
    Picard, Francois
    Pison, Christophe
    Sitbon, Olivier
    Bouvaist, Helene
    Degano, Bruno
    EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (06)
12345